Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07250386 | A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors | PHASE1 | RECRUITING | 48 | — | — | Oct 13, 2025 | Sep 30, 2028 | Nov 26, 2025 | 1 | China |
Incidence of adverse events during the study, evaluated per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) criteria
Dose-limiting toxicity after CEA CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 2-6x10\^5 cells/kg |
| Intrapleural infusion of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 2-6x10\^5 cells/kg |
| Name | Type | Description |
|---|---|---|
| CEA-targeted CAR-T (Intravenous) | BIOLOGICAL | Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion |
| CEA-targeted CAR-T (Intrapleural) | BIOLOGICAL | Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion |
Inclusion Criteria: 1. Aged 18 years or older, of any gender. 2. Histologically or cytologically confirmed advanced, metastatic, or recurrent solid tumors, including non-small cell lung cancer and breast cancer. 3. Disease progression or intolerance after at least second-line standard therapy, incl...